Cargando…

Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals

BACKGROUND: Compatible solutes are natural substances that are known to stabilize cellular functions. Preliminary ex vivo and in vivo studies demonstrated that the compatible solute ectoine restores natural apoptosis rates of lung neutrophils and contributes to the resolution of lung inflammation. D...

Descripción completa

Detalles Bibliográficos
Autores principales: Unfried, Klaus, Krämer, Ursula, Sydlik, Ulrich, Autengruber, Andrea, Bilstein, Andreas, Stolz, Sabine, Marini, Alessandra, Schikowski, Tamara, Keymel, Stefanie, Krutmann, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076798/
https://www.ncbi.nlm.nih.gov/pubmed/27799756
http://dx.doi.org/10.2147/COPD.S115061
_version_ 1782462087334723584
author Unfried, Klaus
Krämer, Ursula
Sydlik, Ulrich
Autengruber, Andrea
Bilstein, Andreas
Stolz, Sabine
Marini, Alessandra
Schikowski, Tamara
Keymel, Stefanie
Krutmann, Jean
author_facet Unfried, Klaus
Krämer, Ursula
Sydlik, Ulrich
Autengruber, Andrea
Bilstein, Andreas
Stolz, Sabine
Marini, Alessandra
Schikowski, Tamara
Keymel, Stefanie
Krutmann, Jean
author_sort Unfried, Klaus
collection PubMed
description BACKGROUND: Compatible solutes are natural substances that are known to stabilize cellular functions. Preliminary ex vivo and in vivo studies demonstrated that the compatible solute ectoine restores natural apoptosis rates of lung neutrophils and contributes to the resolution of lung inflammation. Due to the low toxicity and known compatibility of the substance, an inhalative application as an intervention strategy for humans suffering from diseases caused by neutrophilic inflammation, like COPD, had been suggested. As a first approach to test the feasibility and efficacy of such a treatment, we performed a population-based randomized trial. OBJECTIVE: The objective of the study was to test whether the daily inhalation of the registered ectoine-containing medical device (Ectoin(®) inhalation solution) leads to a reduction of neutrophilic cells and interleukin-8 (IL-8) levels in the sputum of persons with mild symptoms of airway disease due to lifelong exposure to environmental air pollution. METHODS: A double-blinded placebo-controlled trial was performed to study the efficacy and safety of an ectoine-containing therapeutic. Prior to and after both inhalation periods, lung function, inflammatory parameters in sputum, serum markers, and quality-of-life parameters were determined. RESULTS: While the other outcomes revealed no significant effects, sputum parameters were changed by the intervention. Nitrogen oxides (nitrate and nitrite) were significantly reduced after ectoine inhalation with a mean quotient of 0.65 (95% confidence interval 0.45–0.93). Extended analyses considering period effects revealed that the percentage of neutrophils in sputum was significantly lower after ectoine inhalation than in the placebo group (P=0.035) even after the washout phase. CONCLUSION: The current study is the first human trial in which the effects of inhaled ectoine on neutrophilic lung inflammation were investigated. Besides demonstrating beneficial effects on inflammatory sputum parameters, the study proves the feasibility of the therapeutic approach in an aged study group.
format Online
Article
Text
id pubmed-5076798
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50767982016-10-31 Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals Unfried, Klaus Krämer, Ursula Sydlik, Ulrich Autengruber, Andrea Bilstein, Andreas Stolz, Sabine Marini, Alessandra Schikowski, Tamara Keymel, Stefanie Krutmann, Jean Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Compatible solutes are natural substances that are known to stabilize cellular functions. Preliminary ex vivo and in vivo studies demonstrated that the compatible solute ectoine restores natural apoptosis rates of lung neutrophils and contributes to the resolution of lung inflammation. Due to the low toxicity and known compatibility of the substance, an inhalative application as an intervention strategy for humans suffering from diseases caused by neutrophilic inflammation, like COPD, had been suggested. As a first approach to test the feasibility and efficacy of such a treatment, we performed a population-based randomized trial. OBJECTIVE: The objective of the study was to test whether the daily inhalation of the registered ectoine-containing medical device (Ectoin(®) inhalation solution) leads to a reduction of neutrophilic cells and interleukin-8 (IL-8) levels in the sputum of persons with mild symptoms of airway disease due to lifelong exposure to environmental air pollution. METHODS: A double-blinded placebo-controlled trial was performed to study the efficacy and safety of an ectoine-containing therapeutic. Prior to and after both inhalation periods, lung function, inflammatory parameters in sputum, serum markers, and quality-of-life parameters were determined. RESULTS: While the other outcomes revealed no significant effects, sputum parameters were changed by the intervention. Nitrogen oxides (nitrate and nitrite) were significantly reduced after ectoine inhalation with a mean quotient of 0.65 (95% confidence interval 0.45–0.93). Extended analyses considering period effects revealed that the percentage of neutrophils in sputum was significantly lower after ectoine inhalation than in the placebo group (P=0.035) even after the washout phase. CONCLUSION: The current study is the first human trial in which the effects of inhaled ectoine on neutrophilic lung inflammation were investigated. Besides demonstrating beneficial effects on inflammatory sputum parameters, the study proves the feasibility of the therapeutic approach in an aged study group. Dove Medical Press 2016-10-18 /pmc/articles/PMC5076798/ /pubmed/27799756 http://dx.doi.org/10.2147/COPD.S115061 Text en © 2016 Unfried et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Unfried, Klaus
Krämer, Ursula
Sydlik, Ulrich
Autengruber, Andrea
Bilstein, Andreas
Stolz, Sabine
Marini, Alessandra
Schikowski, Tamara
Keymel, Stefanie
Krutmann, Jean
Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals
title Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals
title_full Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals
title_fullStr Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals
title_full_unstemmed Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals
title_short Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals
title_sort reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076798/
https://www.ncbi.nlm.nih.gov/pubmed/27799756
http://dx.doi.org/10.2147/COPD.S115061
work_keys_str_mv AT unfriedklaus reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals
AT kramerursula reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals
AT sydlikulrich reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals
AT autengruberandrea reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals
AT bilsteinandreas reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals
AT stolzsabine reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals
AT marinialessandra reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals
AT schikowskitamara reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals
AT keymelstefanie reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals
AT krutmannjean reductionofneutrophiliclunginflammationbyinhalationofthecompatiblesoluteectoinearandomizedtrialwithelderlyindividuals